FATE Projected Dividend Yield
Fate Therapeutics Inc ( NASDAQ : FATE )Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line. 20 YEAR PERFORMANCE RESULTS |
FATE Dividend History Detail FATE Dividend News FATE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |